{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-25-010510","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2025-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.057622+00:00","generated_at":"2026-05-17T07:24:35.398694+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights","bullets":["Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.","Tenax also obtains manufacturing rights for subcutaneously administered levosimendan products under the expanded license.","Orion will supply levosimendan API at low triple-digit thousand Euros/kg, minimum order [***] grams, payment within 45 days.","Fifth Amendment builds on prior agreements; effective September 3, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-25-010510","json":"https://secwatch.observer/filing/0001654954-25-010510.json","markdown":"https://secwatch.observer/filing/0001654954-25-010510.md","text":"https://secwatch.observer/filing/0001654954-25-010510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/0001654954-25-010510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495425010510/tennx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T07:24:35.398694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}